Back to search results

Nicotine's Effect on Eye Movements in E-Cigarette Users

This study, called NICS-EYES, is looking at how nicotine affects eye movements and related behaviors in people who use e-cigarettes. Nicotine is an addictive chemical found in tobacco and e-cigarettes. Researchers want to understand how nicotine influences eye movements, which could help evaluate how addictive a nicotine product is. You might be able to join if you are 21-50 years old and use nicotine-containing e-cigarettes daily. The main goal is to see how reliable eye movement measurements are after nicotine use. This study is currently recruiting about 25 participants, but the recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 25 participants. It is not specified if it is randomized or blinded.
What's involved
You would complete two in-person visits, abstaining from nicotine for at least 12 hours and caffeine for 2 hours before each. You will use an e-cigarette, have eye movement tests, and give blood samples.
Compensation
Not stated in the trial record.
Follow-up
Eye movement changes will be assessed up to the completion of visit 2, which is up to 3 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07604246

Evaluating the Effect of Nicotine on Eye Movements and Related Behaviors in Electronic Cigarette Users, NICS-EYES Trial

Not Yet Recruiting
NAAges 21–50InterventionalBasic science
Ohio State University Comprehensive Cancer Center
~25 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:AvoidanceBiospecimen CollectionCigarette SmokingEye Movement MeasurementHealthcare ActivityQuestionnaire Administration

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in prosaccade latency and velocity
Measured over At baseline and at 5, 15 and 30 minutes post-nicotine administration, assessed up to completion of visit 2, up to 3 weeks
+7 more outcomes measured

Conditions

Cigarette Smoking-Related Carcinoma

Explore related trials

Electronic Cigarette Use

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Patrick Tomko, PhD, CSCS · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center

Who to contact

The Ohio State University Comprehensive Cancer Center
[email protected]
800-293-5066
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 21-50 years
Daily use of nicotine-containing electronic cigarettes for ≥ 6 months
Ability to abstain from nicotine for at least 12 hours prior to study visits
Fluent in English
Willingness to complete two in-person laboratory visits and all study procedures
Ability to provide informed consent

Exclusion

Use of combustible cigarettes or other tobacco/nicotine products on more than 5 of the past 30 days
Current enrollment in a nicotine cessation program or intent to quit in the next 30 days
Neurological conditions affecting eye movements (seizure disorder, movement disorders, head injury with loss of consciousness)
Normal or corrected-to-normal vision required; significant uncorrected visual impairment or ocular conditions affecting eye tracking
Cardiovascular conditions for which nicotine use is contraindicated, substance use disorder (other than nicotine), or current nicotine cessation treatment
Pregnancy or breastfeeding
Current medications affecting pupil size or eye movements (anticholinergics, stimulants, antipsychotics)
Any condition that, in the investigator's judgment, would interfere with safe participation
Age younger than 21 years or older than 50 years

What this trial measures

  • Change in prosaccade latency and velocityAt baseline and at 5, 15 and 30 minutes post-nicotine administration, assessed up to completion of visit 2, up to 3 weeks

    Reliability will be assessed using intraclass correlation coefficients (ICCs). Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures analysis of variance (ANOVA), as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.

  • Change in antisaccade error rate and latencyAt baseline and at 5, 15 and 30 minutes post-nicotine administration

    Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.

  • Change in smooth pursuit gain across two laboratory sessionsAt baseline and at 5, 15 and 30 minutes post-nicotine administration

    Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.

  • Change in oculomotor performanceAt baseline and at 5, 15 and 30 minutes post-nicotine administration

    Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.

  • Plasma nicotine maximum concentrationUp to completion of visit 2, up to 3 weeks

    Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.

  • Time to maximum concentration of plasma nicotineUp to completion of visit 2, up to 3 weeks

    Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.

  • Plasma nicotine area under the curveUp to completion of visit 2, up to 3 weeks

    Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.

  • Subjective drug liking ratingsUp to completion of visit 2, up to 3 weeks

    Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between subjective ratings and behavioral economic measures will be examined using correlation and regression analyses.